1.1Cyano substituted phenyl ring
The phenyl ring provides a planar aromatic surface. The nitrile nitrogen provides a hydrogen-bond acceptor outside the ring, two ring bonds from the scaffold attachment site.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The phenyl ring provides a planar aromatic surface. The nitrile nitrogen provides a hydrogen-bond acceptor outside the ring, two ring bonds from the scaffold attachment site.
The scaffold attaches to a bridgehead carbon of the saturated bicyclic group. Three ethylene bridges hold the group in a rigid shape and provide a nonpolar contact surface.
The nitrile projects from the para carbon along the long axis of the substituted phenyl group. Its terminal nitrogen provides a hydrogen-bond acceptor, and the carbon–nitrogen triple bond contributes a local dipole.
The scaffold bonds directly to one carbon of the three-membered ring. The two remaining ring carbons form a compact hydrophobic group with a fixed internal geometry.
The group attaches through a scaffold–sulfur bond and terminates in —SO₂NH₂. Its sulfonyl oxygens provide hydrogen-bond acceptor sites, and its NH₂ group provides a donor site.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A cultured sensory neuron assay uses a compound of formula (I) as a reference for sodium channel blockade during electrical stimulation. Separate wells receive vehicle, the reference compound, or a test material. A microelectrode array records evoked spike counts before and after exposure, and the reference wells show how the assay responds to a sodium channel blocker.
A thiazol-2-yl group replaces a pyridyl group at position A and attaches to the scaffold through carbon 2 of the thiazole ring. The B and C rings and the R1 and R2 groups are identical in the two compounds. Whole-cell voltage clamp measures Nav1.8 current over the same concentration series for both compounds.
A pyrrolidin-1-ylcarbonyl group replaces the primary carboxamide at R2 and retains the bond from the scaffold to the carbonyl carbon. The amide nitrogen forms part of the five-membered pyrrolidine ring, and positions A, B, C, and R1 match those of the primary carboxamide. Liquid chromatography measures the dissolved concentration of each compound in assay buffer, and voltage-clamp recordings compare Nav1.8 current at matched dissolved concentrations.
A whole-cell voltage clamp assay delivers trains of 20 depolarizing pulses at 1, 5, and 10 Hz to cells expressing Nav1.8. Each pulse steps from −100 mV to +10 mV for 20 ms, and the cell rests at −100 mV for 60 seconds between trains. At each frequency, the ratio of the twentieth peak current to the first is compared between compound and vehicle recordings.
A two-compartment microfluidic chip holds sensory neuron cell bodies in one chamber and guides their axons through microgrooves into a separately perfused chamber. The axon chamber receives a solution containing a compound of formula (I), while the cell body chamber receives vehicle. An extracellular electrode stimulates the axons upstream of the exposed segment, and an electrode in the cell body chamber records the fraction of pulses that produce a propagated spike.
A liquid handler prepares an eight-point, threefold dilution series of a compound of formula (I) and dispenses it into an automated patch-clamp plate containing cells that express Nav1.8. The instrument records peak inward current before and after compound exposure, and software normalizes each response to its baseline and the time-matched vehicle response. The software fits a four-parameter logistic curve and reports the concentration at the midpoint when the measured responses span that midpoint.
A is a pyridin-2-yl group bearing trifluoromethyl at ring position 5. The substituent attaches through its carbon and contains three fluorines on that carbon.
An oxetan-3-yl substituent attaches to A through the carbon opposite the ring oxygen. The saturated four-membered ring contains three carbons and one ether oxygen.
B is a phenyl group bearing —CD₃ at the carbon para to the scaffold attachment. All three hydrogen positions on the methyl carbon are occupied by deuterium.
C is an unsubstituted pyridin-3-yl group linked to the scaffold through pyridine carbon 3. The aromatic ring nitrogen occupies position 1 and provides a hydrogen-bond acceptor.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A compound of formula A or its prodrugs, tautomeric forms, stereoisomers, optical isomers, pharmaceutically acceptable salts, solvates or polymorphs thereof, wherein is 5-membered heterocyclic ring substituted with alkyl chain at 2 or 3, or 8-10 membered bicyclic group wherein a six membered heterocyclic ring is fused with 5-membered heterocyclic ring; represents a 5-10 membered monocyclic or bicyclic heteroaryl ring, 5-10 membered monocyclic or bicyclic heterocycloalkyl grouA · US 2014/0249170 A1 · claim 1
W, Y and Z are independently selected from nitrogen atom and carbon atom, which are independently optionally substituted with R1; at least one of W, Y and Z is nitrogen and W, Y and Z are not carbon at the same time;B · US 2015/0322052 A1 · claim 14
R3, R4, R5 and R6 are independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen, (4) C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (5) C3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (6) —O—C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (7) —O—CB · US 2015/0322052 A1 · claim 14
R9 and R10 are independently hydrogen or C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, and —O—C1-6 alkyl; or R9 form a 4 to 7 membered ring with R10 which may contain nitrogen atom, oxygen atom, sulfur atom or double bond, wherein the 4 to 7 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogenB · US 2015/0322052 A1 · ¶ 51
L is selected from H, alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl;A · US 2014/0249170 A1 · ¶ 13
Ar is aryl which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of: (1) halogen, (2) hydroxyl, (3) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (4) —NR9R10, and (5) —CN; wherein n is 0 or 1; when n is 0, a chemical bond is present in the place of On; or a pharmaceutically acceptable salt thereof.B · US 2015/0322052 A1 · claim 14
R is selected from small alky group or halogen substitution;A · US 2014/0249170 A1 · claim 1
wherein E3 is selected from the group consisting of —CH2—, NH, NMe and O; and R1 and R2 are independently selected from the group consisting of methyl, ethyl, n-propyl and alkyl chain (C4-C9).A · US 2014/0249170 A1 · ¶
(1) hydrogen, (2) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (3) —On—C1-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R7, and (4) —On-heterocyclic group, where the heterocyclic group is unsubstituted or substituted with one or more substituents independently selected from R7; wherein n is 0 or 1, when n is 0, a chemiB · US 2015/0322052 A1 · claim 14
wherein E3 and E4 are independently selected from the group consisting of —CH2— and NH and N with the proviso that both E3 and E4 are NH or one of E3, E4 is NH or one of E3, E4 is NH while one of E3, E4 is N—X-L and R3 is selected from a group consisting of small alkyl group comprising methyl, ethyl or n-propyl and 3-6 membered cycloalkyl ring.A · US 2014/0249170 A1 · ¶
An empty cell means only that no passage was reproduced there.
Given the high level of drug resistance and the large unmet clinical need, novel agents to treat S. aureus infections are urgently needed.A · US 2014/0249170 A1 · ¶ 6
This invention is related to novel compounds which specifically inhibit bacterial FabI for the treatment of Staphylococcal infections.A · US 2014/0249170 A1 · ¶ 2
The present invention relates to aryl substituted carboxamide derivatives which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved.B · US 2015/0322052 A1 · ¶ 1
The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.B · US 2015/0322052 A1 · ¶ 1
patent.fyi, US 2026/0356804 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356804/, SHA-256 838df3d7670e2ad2ed22518c7e7619d4e900b0c4a7da01e3849c08d59d0a465d